background: firoozgar comprehensive stroke center started up as the first organized care unit in the country in 2014; this study was performed to investigate quality indicators such as reduction in mortality, morbidity and hospital stay.   methods: two groups of ischemic stroke patients were compared. the first group had been admitted in general neurology ward (non-stroke unit patients) and the...

Submit Manuscript | http://medcraveonline.com Abbreviations: UAE: United Arab Emirates; NINDS rtPA: Neurological Disorders and Stroke recombinant tissue plasminogen activator; tPA: tissue Plasminogen Activator; CT: Computerized Tomography; mRS: modified Rankin Scale; TOAST: Trial of Org 10172 in Acute Stroke Treatment criteria; NIHSS: National Institute of Health Stroke Scale; SPSS: Statistical...

Abbreviations: ACD 5 absolute claudication distance; CI 5 confidence interval; INR 5 international normalized ratio; LMWH 5 low-molecular-weight heparin; MI 5 myocardial infarction; NASCET 5 North American Symptomatic Carotid Endarterectomy Trial; PGE1 5 prostaglandin E1; PGI2 5 prostaglandin I2; PTFE 5 polytetrafluoroethylene; rtPA 5 recombinant tissue plasminogen activator; tPA 5 tissue plasm...

BACKGROUND Information about treatment protocols, adverse effects and outcomes with intrapleural recombinant tissue plasminogen activator (rTPA) use in horses with fibrinous pleuropneumonia is limited. HYPOTHESIS/OBJECTIVES Describe factors that contribute to clinical response and survival of horses treated with rTPA intrapleurally. ANIMALS Horses with bacterial pneumonia and fibrinous pleu...

M ore than half of ischemic stroke patients who are treated with IV recombinant tissue-type plasminogen activator (rtPA) remain disabled at 3 months. The reasons are many. The IV rtPA rate of recanalizing occluded arteries is not as high as we would like, especially for large arterial occlusions, which are opened only 30% to 40% of the time. 3–6 When rtPA does effectively lyse a thrombus, it is...

KEY CLINICAL MESSAGE We report a comatose patient with severe neurological deficits who was without spontaneous language or movement. He had a good response to recombinant tissue plasminogen activator (rtPA) thrombolysis even though there were no detectable lesions on diffusion-weighted imaging (DWI). DWI is very sensitive for diagnosing hyperacute ischemic stroke, and rtPA thrombolysis is the ...

The effect of recombinant human tissue plasminogen activator (rtPA) on neuroinflammation after stroke remains largely unknown. Here, we tested the effect of rtPA on expression of cellular adhesion molecules, chemokines, and cytokines, and compared those with levels of inflammatory cell recruitment, brain injury, and mortality over 3 days after transient middle cerebral artery occlusion (MCAO) i...

stroke is an important cause of disability and death worldwide, with the majority of strokes occurring in older people. thrombolysis with recombinant tissue plasminogen activator (r-tpa) is the approved treatment for acute ischemic stroke. a major concern of physicians, who treat acute ischemic stroke with recombinant tissue plasminogen activator (r-tpa,) is the risk of intracerebral hemorrhage...

The sole FDA-approved treatment for acute stroke is recombinant tissue-type plasminogen activator (rtPA). However, rtPA aggravates the impairment of cerebrovasodilation induced by global hypoxia/ischemia; this impairment is attenuated by the preinjury treatment with the plasminogen activator inhibitor derivative EEIIMD. MAPK (a family of kinases, p38, and JNK) is upregulated after cerebral isch...

no abstract